Weaker-than-expected Q2 + lacklustre guidance
08/05/24 -"CZM reported soft Q2 results with both sales and adjusted EBIT missing the street’s expectations. The mid-single-digit sales decline was due to weakness in Ophthalmology while Microsurgery ..."
Pages
67
Language
English
Published on
08/05/24
You may also be interested by these reports :
17/05/24
Clariane communicated more details regarding its projected capital increases and the entry of a new anchor shareholder in its capital. We take this ...
17/05/24
We have incorporated the detailed information provided by Clariane regarding its projected capital increases. This has resulted in only minor changes ...
16/05/24
On the back of the promising beginning to 2024, which was a combination of 1/ normalising market demand in Europe (the lynchpin geography); 2/ the ...
16/05/24
As we have consistently argued over the last 3 years, Health stocks (ex Pharma) are long on growth promises and short on delivery. The gap stems from ...